OCA
NGM

Octagon Capital Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Octagon Capital Advisors’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-200,000
Closed -$4.2M – 35
2021
Q3 		$4.2M Hold
200,000
– – 1.04% 22
2021
Q2 		$3.94M Hold
200,000
– – 0.82% 31
2021
Q1 		$5.81M Buy
200,000
+124,773
+166% +$3.49M 2.19% 19
2020
Q4 		$2.28M Buy
+75,227
New +$1.65M 0.79% 28

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Octagon Capital Advisors's NGM Position: Q4 2021 in Review

Octagon Capital Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2021, closing a stake of 200,000 shares — an estimated $4.2M sold.

Octagon Capital Advisors first reported a position in NGM in Q4 2020 and held it in 4 quarters. The position peaked at $5.81M in Q1 2021. 119 funds tracked by Wall St. Rank hold NGM as of Q4 2021.

  • Octagon Capital Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 200,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $4.2M.
  • Octagon Capital Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Octagon Capital Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $5.81M in Q1 2021.
  • 119 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Octagon Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.